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Abstract
The exosome complex is the most important RNA processing machinery within the cell. Mutations in its subunits EXOSC8
and EXOSC3 cause pontocerebellar hypoplasia, spinal muscular atrophy (SMA) and central nervous system demyelination.
We present a patient with SMA-like phenotype carrying a homozygous mutation in RBM7—a subunit of the nuclear exosome
targeting (NEXT) complex—which is known to bind and carry specific subtypes of coding and non-coding RNAs to the exo-
some. The NEXT complex with other protein complexes is responsible for the substrate specificity of the exosome. We per-
formed RNA-sequencing (RNA-seq) analysis on primary fibroblasts of patients with mutations in EXOSC8 and RBM7 and gene
knock-down experiments using zebrafish as a model system. RNA-seq analysis identified significantly altered expression of
62 transcripts shared by the two patient cell lines. Knock-down of rbm7, exosc8 and exosc3 in zebrafish showed a common pat-
tern of defects in motor neurons and cerebellum. Our data indicate that impaired RNA metabolism may underlie the clinical
phenotype by fine tuning gene expression which is essential for correct neuronal differentiation.
Introduction
The exosome complex is a major component in degradation,
maturation and quality control of almost any type of RNA
within the cell, and therefore plays a major role in gene ex-
pression regulation (1). The exosome is a large multi subunit
complex whose functions are highly conserved throughout all
forms of life (2). In eukaryotes it is composed of nine subunits,
six of them forming the core of the protein complex through
which the RNA will pass in a 30–50 direction (Rrp41/EXOSC4,
Rrp42/EXOSC7, Rrp43/EXOSC8, Rrp45/EXOSC9, Rrp46/EXOSC5
and Mtr3/EXOSC6) and three of them forming the cap of the
exosome (Rrp40/EXOSC3, Csl4/EXOSC1 and Rrp4/EXOSC2) with
RNA binding properties (3). As previously mentioned, the exo-
some complex performs a number of functions related to gene
expression regulation through RNA decay (4). Other than being
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engaged in 30–50 degradation of normal mRNAs, it degrades
mRNA which contain AU-rich elements (AREs) (5). The exo-
some also degrades defective mRNAs through different path-
ways: the ‘nonsense-mediated’ decay (NMD) pathway, which
degrades mRNAs with a premature stop codon (6), the ‘non-
stop’ decay pathway (NSD) degrades mRNAs that lack a termi-
nation codon (7), and the ‘no-go’ decay pathway (NGD) which
targets mRNAs on which translation has stopped (8). More re-
cently it has been shown that the exosome complex is in-
volved in the metabolism of many types of non-coding RNAs
(9). The exosome complex deals with such a high variety of
substrates through the interaction with different co-factors
which bind specific subtypes of RNA (10). One of the main co-
factors is the trimeric Trf4/5p-Air1/2p-Mtr4p polyadenylation
(TRAMP) complex. The two catalytic activities of the TRAMP
complex are carried out by TRf4-Air2—a poly(A)polymerase
sub-complex - and helicase Mtr4 (11). MTR4 co-purifies with
the exosome complex in yeast (12). Human homologs of the
TRAMP components, in addition to hMTR4, might be hTRF4-1
(POLS) and hTRF4-2 (PAPD5) (12) and ZCCHC7 (Air2) (13) al-
though experimental evidence is lacking.
The human MTR4 together with an RNA-binding protein
(RBM7) and a Zn-knuckle protein (ZCCHC8) forms another tri-
meric complex, the nuclear exosome targeting (NEXT) complex
(12). NEXT is present in the nucleoplasm to assist the exosome-
driven degradation of PROMoter uPstream Transcripts (12) and
other non-coding RNAs (14).
The superkiller (SKI) complex co-operates with the exosome
in the cytoplasm. The SKI complex in yeast is a hetero-tetramer
formed by one copy of Ski2 and Ski3 and two copies of Ski8 (15)
and seems to be involved in degradation of defective mRNAs
through the NMD, NSD, and NGD pathways (10). It is not fully
understood how the SKI complex works in humans as the pro-
tein which mediates the interaction between the exosome and
SKI (Ski7p) in yeast has not been identified in humans.
However, a paralog of Ski7p, Hbs1p, which does have an
ortholog in humans might take over the role of Ski7p (10).
Correct processing of mRNAs as well as non-coding RNAs is
known to be fundamental for normal cellular functions (16).
Wan et al. (17) showed for the first time that mutations in the
exosome complex can cause human disease, when they re-
ported mutations in the EXOSC3 sub-unit of the exosome in
pontocerebellar hypoplasia and spinal muscular atrophy
(SMA) (PCH1), accounting for about 40% of cases worldwide
(18). Our group subsequently identified mutations in EXOSC8
which are responsible for the development of overlapping
symptoms of PCH, SMA and central nervous system (CNS) de-
myelination (19). In the last 2 years several other studies indi-
cated that mutations in EXOSC3 result in a more variable
clinical presentation, suggesting that exosome complex dys-
function is a major cause of severe childhood onset complex
inherited neurological disorders. More recently, also muta-
tions in EXOSC2 found in two unrelated German families were
shown to cause neurodevelopmental defects such as mild cer-
ebellar atrophy and cerebellar hypoplasia, diffuse dysmyelina-
tion, hearing loss, mild intellectual disability, facial anomalies
and premature ageing (20).
In this study, we present a patient with a SMA-like phenotype
with a homozygous mutation in RBM7, a co-factor of the exosome
complex (c.236C > G; p.Pro79Arg). In order to understand the dif-
ferent roles of different components of the exosome complex and
its co-factors in neurodevelopment we performed analysis in hu-
man cells carrying mutations in exosomal proteins and in rbm7,
exosc3 and exosc8 knock-down zebrafish (Danio rerio).
Results
Patient
The patient is the youngest of seven siblings to consanguineous
Palestinian parents. Family history is negative for similarly af-
fected children. Pregnancy, delivery and perinatal course were un-
eventful except for breech presentation which necessitated
caesarean section. Initial concerns were raised around one month
of age as hypotonia with poor sucking and failure to thrive were
observed. No developmental regression or cognitive difficulties
were noted but gross motor abilities plateaued around 1 year of
age when unsupported brief sitting was achieved. At this time the
patient was brought to our clinic where examination revealed an
alert child with no dysmorphic features, but cachexia (weight
6.025 kg,<10 percentile; height 70.7 cm,<10 percentile; head cir-
cumference 43.2 cm,<3 percentile) with reduced muscle mass
and decreased tendon reflexes. No tongue fasciculations, or poly-
mini-myocloni were noted. Muscle weakness, both proximal and
distal was apparent (3/5 for most muscle groups tested).
Respiratory difficulties were evident from a few months of age on-
wards and mechanical ventilation became necessary during inter-
current illnesses due to hypercapnia and hypoxemia, though
weaning was successful several times. During the last episode of
respiratory decompensation at age of 28 months the patient died.
Brain MRI was normal. Muscle biopsy detected including fibre
type grouping of small and hypertrophic fibres, compatible with
SMA as shown in Figure 1A and B. No other significant alterations
were evident on H&E, GTC, ATPase9.4, ATPase4.3, NADH, SDH/
COX, PAS, PASþD and ORO stains. Paraffin embedded sections
displayed sheets of foamy macrophages (CD68-immunopositive),
and only few myofibers, consistent with macrophagic myofascii-
tis. electromyography/nerve conduction velocity (NCV) was also
compatible with SMA showing very low CMAPs with chronic early
and late re-innervation with otherwise normal NCV motor and
sensory studies. SMN1 analysis showed two normal copies.
Routine laboratory results including serum creatine kinase and
cardiac echo were normal.
Genetic Analysis
Whole exome sequencing analysis detected a
homozygous mutation in RBM7
Whole exome sequencing (WES) of the patient yielded 58.1 mil-
lion mapped reads with a mean coverage of X86. Following align-
ment and variant calling, we performed a series of filtering steps.
These included removing variants called <8, were off-target,
synonymous, heterozygous, MAF > > 1% at ExAC (Exome
Aggregation Consortium, Cambridge, MA, (URL: http://exac.broad
institute.org)) or MAF > 4% at the Hadassah in-house database
(800 ethnic matched exome analyses). 31 variants survived this
analysis but only 11 remained (Supplementary Material, Table S1)
after removal predicted benign variants (Mutation Taster). Using
Sanger sequencing, we then confirmed segregation within the
family for the RBM7 and the SNX15 variants (Supplementary
Material, Table S2). The human RBM7 gene is located on chromo-
some 11, has 5 exons and encodes 5 different isoforms. The lon-
gest isoform codes for a 266 amino acid protein (NM_016090.3,
AF156098.1). The mutation c.236C > G; p.Pro79Arg is located
within the highly conserved RNA Recognition Motif (RRM) do-
main (14) and is predicted to be pathogenic, affecting the struc-
ture of the binding domain (Fig. 1C) as well as the splice site
(according to MutationTaster), decreasing the stability of the pro-
tein structure (MuPro—http://www.ics.uci.edu/baldig/mutation.
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html; Confidence Score: 0.068480655 and Confidence Score: 0.
644794635393117). In silico analysis with PROVEAN (http://pro
vean.jcvi.org/index.php) also predicted the mutation to be delete-
rious with a score of 4.49. Align-GVGD (http://agvgd.iarc.fr/
agvgd_input.php) scored it Class C65 (most likely to interfere with
protein functions). This variant has not been detected to date in
any of the large databases. Another homozygous variant was de-
tected in the patient in the SNX15 gene. This variant has been re-
ported with very low frequency previously (Supplementary
Material, Table S1). Mutations in SNX15, a novel sorting nexin in-
volved in protein trafficking (21) have not been associated with
human disease to date, and recent data suggests that this protein
is important for cell surface recycling of APP and Ab generation
(22). Given its function, it is more unlikely to be causative for the
SMA-like phenotype, however we cannot exclude completely
that it contributes to the clinical manifestation of the disease.
Extensive search for similar patients with mutations in RBM7
could not be identified despite we screened 24 further patients
with SMA phenotype, where SMN1 testing was negative and
searched over 1000 exome sequencing analysis of patients with
neuromuscular or neurogenetic disease, suggesting that RBM7 is
a rare cause of SMA-like disease.
Immunoblotting
Significantly reduced level of the RBM7 protein (63% reduction)
was detected in patient fibroblasts compared with three healthy
controls, and RBM7 was also reduced in another fibroblast cell
line carrying a pathogenic mutation in EXOSC8 (19) (Fig. 1D).
Immunoblotting for SNX15 detected normal protein levels (data
not shown). Considering the function of the two proteins in the
cell, the similarity of clinical features of this patient and the
EXOSC8 patients, and the reduced protein levels of RBM7 but
not SNX15 in patient cells, we conclude that the RBM7 variant is
more likely to be the disease causing mutation in this patient.
RNA-seq analysis
For each sample, at least 13 million read pairs were mapped to the
transcriptome with their strands matched to the annotated tran-
scripts. As expected, there was a reduction in the levels of the
EXOSC8 transcript in the EXOSC8 cells (Fig. 2A), compared with the
control, but not in the RBM7 cells (data not shown). Hierarchical rep-
resentation of the samples showed how most of the triplicates clus-
tered together (Fig. 2B). RNA-seq analysis showed a > -fold change
in gene expression of several protein coding genes and non-coding
RNAs, 62 of which are being shared between EXOSC8 and RBM7 mu-
tant primary fibroblasts (Fig. 2C and D, Supplementary Material,
Table S4). Interestingly, pathway analysis of the shared RNAs
showed pathways related to the nervous system (Fig. 2E).
Gene expression of HOXC genes was altered in human
fibroblast with EXOSC8 and RBM7mutations
In order to verify RNA-seq data we performed qRT-PCR analysis
of four transcripts which were upregulated in the RNA-seq
Figure 1. Frozen sections stained with immunohistochemical stains for slow- (A) and fast-myosin (B) display striated muscle tissue with large group atrophy, including
atrophic myofibers of both types, alongside groups of hypertrophic myofibers, most of them type 1. The c.236C > G; p.Pro79Arg mutation identified by Sanger sequenc-
ing is predicted to be pathogenic by Mutation Taster (58); (C). The mutated amino acid is located in the RRM domain just before the last b strand forming a four stranded
Antiparallel b-sheet. The 3D model was built using Phyre2 according to the structure presented by Hrossova et al., 2015. Immunoblotting of fibroblasts of the patient
with RBM7 mutation and EXOSC8 mutant fibroblasts showed reduced RBM7 protein levels in both patients compared with three control fibroblast lines (D).
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analysis. Correlation analysis between RNA-seq and qRT-PCR
data of HOTAIR, HOXC6, HOXC8, HOXC9 confirmed a high degree
of correlation between the two sets of data (RBM7: R2¼0.9806;
EXOSC8: R2¼0.9973, Fig. 3). We detected no significant changes in
genes associated with motor neuron and Purkinje cell (PC) dys-
function or myelination that could be expected from the pheno-
type of the RBM7 and EXOSC8 patients. This could be explained
by tissue specific differences, as these genes might not be ex-
pressed in fibroblasts.
Abnormalities in morphant zebrafish resemble the
clinical phenotype of patients with exosomal protein
deficiencies
In order to verify RNA-seq data from human fibroblasts, we de-
cided to use zebrafish as a model system for exosomal protein
deficiencies. Zebrafish is considered an excellent animal model
for investigation of neurodevelopmental disorders (23) and has
been previously used to study cerebellar development (24),
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Figure 2. Transcriptomic characterization of fibroblasts carrying mutations in RBM7 and EXOSC8. (A) Levels of EXOSC8 transcripts of patient with the c.5C>T, p.Ala2Val
EXOSC8 mutation and control fibroblasts. Relative corrected counts are represented. (B) Hierarchical clustering dendrogram for RNA-seq data for all covered genes for
the 3 biological triplicates of each cell line. The range of colours between blue and green represent the number of corrected counts. (C) Venn diagram showing the share
genes between the differentially expressed genes of both comparisons. (D) Heat map of the distribution of the corrected values of the shared genes. HOX genes are
highlighted. Red represented higher counts, white middle and blue lower counts, across the comparisons. (E) Pathway enrichment analysis performed in the 62 shared
genes by Panther pathway analysis.
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hindbrain (25) as well as motor neurons (26). The lightly pig-
mented golden strain and islet1:GFP transgenic zebrafish were
chosen to perform downregulation of rbm7, exosc8 and exosc3.
MOs for exosc3 and exosc8 have been previously reported and re-
spective morphants were phenotypically characterized (17,19).
Our database search (ENSDARG00000020841.7, NM_199925.1)
identified a single rbm7 gene in the zebrafish genome encoding
a 252 amino acid protein located on chromosome 18. Although
the overall homology between the human and zebrafish RBM7
protein is relatively low (41% identical and 55% similar protein
sequences) and also the mutated amino acid is not conserved
between the two species (it is substituted with a glutamine in
zebrafish), if only the highly conserved region of the RRM (the
first 94 amino acids in human, the first 93 in zebrafish) is con-
sidered, the degree of homology is much higher (14) (69.5% iden-
tity and 84% similarity, Supplementary Material, Figure S1).
To knock down rbm7, we designed an antisense MO to target
the intron1-exon2 boundary (Fig. 4A), which caused a range of
different phenotypes and morphant fish were classified in three
classes according to the severity of the phenotype (mild, moder-
ate, severe). Injection of rbm7-MO caused a series of developmen-
tal defects. Even the mildly affected fish were unable to swim
away normally upon touch stimulation compared with the con-
trol fish (supplementary videos). The body shape was slightly
shorter and sporadically brain oedema could be observed. The
moderately affected fish had a curved body shape, smaller head
and eyes compared with control fish. Heart and brain oedema
were frequently observed. In fish with severe phenotype the body
shape was completely altered, the tail was absent, and the head
and eyes were smaller. Co-injection of rbm7-MO (2.2 ng) with p53-
MO (5 ng) in order to reduce apoptosis did not significantly reduce
the high mortality rate within the first 24 h, which seems to
Figure 3. Gene expression analysis of four genes through qRT-PCR confirmed RNA-seq data. RNA-seq data and qRT-PCR show a high correlation. The qRT-PCR data
show relative expression of target genes in RBM7 and EXOSC8 mutant fibroblasts compared with control fibroblasts. Analysis was repeated on three biological
replicates.
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happen after 12 hpf. The number of dead fish in the control MO
injected group was not much different from control un-injected
fish, indicating that the mortality was caused by the rbm7 MO.
We designed a second morpholino to target exon2-intron2
boundary, and could obtain a very similar phenotype, indicating
that the phenotype is specific for rbm7 knock down.
Hindbrain nuclei were altered in islet1:GFP morphant
zebrafish
Downregulation of all three genes led to brain abnormalities in
islet1:GFP fish (Fig. 4B), resembling what previously observed by
us in an exosc8-MO zebrafish model (19) and by others in a zebra-
fish model of SMA (27). Down-regulation of rbm7 has a milder ef-
fect on more rostral cranial motoneurons, affecting specifically
the nuclei of the vagal brachimotor neurons (X) even in the mild
phenotype. Knock down of exosc3 affects most severely the mi-
grating brachimotor facial neurons (VII) while other areas are
relatively less compromised. Disruption of hindbrain organiza-
tion in exosc8-MO-treated fish is more generalized showing scat-
tered structures without any recognizable anatomical area in
moderately affected. A little effect was observed on hindbrain de-
velopment in exosc8-MO mildly affected fish, but the brain phe-
notype becomes more prominent in parallel with the severity of
the changes in overall body morphology. Knock-down of the
three genes shows interestingly that, although overall the ana-
tomical structures of the hindbrain were disrupted in all three
morphants, knock-down of different genes caused more severe
impairment in different hindbrain areas.
Imaging of motor neurons and PCs in goldenmorphant
zebrafish detected characteristic abnormalities
resembling PCH1
We performed whole mount immunohistochemistry in zebra-
fish embryos and larvae at 4.5 dpf and 48 hpf to investigate the
Figure 4. Morphological defects caused by injection of rbm7 MO (A). Mild phenotype fish show slight developmental delay, and shorter body length. Rostrally the head
is smaller than control fish while caudally the head looks slightly swollen. Body shape in the moderate phenotype looks compromised and head oedema increased,
sporadically we could observe heart oedema as well. Body shape of the severe fish is completely disrupted, swelling of the head is more severe, and we detected
smaller forehead and eyes compared with control fish (Scale bar¼200 lm). On the bottom left: RT-PCR of zebrafish cDNA shows efficacy of morpholino against In1-Ex2
boundary. Position of morpholinos is explained in the graph on the right. Below: graphs showing mortality and phenotype rates at 24 hpf. (B) Hindbrain defects in mor-
phant fish. Cranial motor neurons nuclei are well defined in 5 nuclei in wild type fish: Oculomotor neurons (III), Trochlear neurons (IV), Trigeminal neurons (V), Facial
neurons (VII), Vagal neurons (X). rbm7-MO seems to have a milder effect on cranial motor-neurons development and to affect predominantly vagal nucleus (nX) which
result shorter than controls. Hindbrain structures in exosc8-MO are more generally affected the moderate phenotype fish. Only nX is partially preserved. Exosc3-MO af-
fects predominantly nVII (facial neurons) (Scale bar¼200 lm).
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role of rbm7, exosc8 and exosc3 in the development of the periph-
eral and CNS in order to find similarities with the human phe-
notype. We used antibodies against Pvalb7 (a kind gift of
Professor Masahiko Hibi, Nagoya University, Japan), a marker of
PCs in the cerebellum and SV2 antibody and a-bungarotoxin
which bind, respectively to presynaptic vesicles and AChRs al-
lowing the visualization of neuromuscular junction (Fig. 5).
We observed a similar pattern of cerebellar disruption upon
injection of all three MOs but in different proportions (Fig. 5A
and B, E and F, I). Only fish with a mild and moderate phenotype
were considered for this experiment, because of non-specific
changes are frequent in severely altered embryos. The structure
of PC layer showed scattered cells instead of a typical wing-
shaped structure, in all 3 MO treated fish. About 75–100% of the
exosc3-MO and exosc8-MO and <50% of rbm7-MO-treated fish
showed defective structures (Fig. 5I).
Staining of neuromuscular junctions showed overlap of
presynaptic and postsynaptic structures and defective growth
of motor neuron axons in all three morphants (Fig. 5C and D, G
and H, 5J). Many of the fish have one or more axons truncated
at about 1/3 to 1/2 of the thickness of the body (Fig. 5J).
Interestingly, only exosc8-MO fish showed defective branching
of motoneurons which divide in two branches after about one-
third of the total length (Fig. 5G). The reduced length of the
Figure 5. Confocal microscopy analysis of PCs (A,B,E,F) and neuromuscular junctions (C,D,G,H) in zebrafish upon injection of three different MOs. PCs fail to differenti-
ate in rbm7-MO (B), exosc8-MO (E) and exosc3-MO (F) zebrafish compared with ctrl-MO fish (A). The percentage of fish with cerebellar defects varies significantly be-
tween morphants, reflecting what observed in patients. Motor axon growth is defective in all three morphants (D,G,H); arrows point at abnormally short motor axons.
Interestingly, only in exosc8-MO the motor neuron axon branches in close proximity of the spinal cord instead of more ventrally as in the ctrl-MO fish (G). Scale
bar¼100 lm. We show the quantity and respective percentage of fish with cerebellar defects (I). Axonal defects in different morphant and phenotypical classes (only
mild and moderate phenotypes were considered for this analysis) (J). The number of defective structures increases with the severity of the phenotype.
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motor neuron axons was statistically significant
(Supplementary Material, Figure S2).
Gene expression analysis in zebrafish
Based on the increased expression of the HOXC genes in human
cells and their role in neuronal development we performed
gene expression analysis by qRT-PCR of HOX genes in rbm7,
exosc8 and exosc3 morphant zebrafish. We did not detect any sig-
nificant difference compared with control fish (data not shown).
Although some of the analysed HOX genes were up or down-
regulated upon gene knock down, the difference was always
<2-fold change.
Interestingly, expression of atxn1b (but not atxn1a) resulted
to be several folds upregulated upon knock down of all three
genes in zebrafish. In silico analysis of the sequences of atxn1a
and atxn1b with ARE score (http://arescore.dkfz.de/arescore.pl)
searching for the level of AU content showed that atxn1b has a
very high ARE score, similar to humans, while atxn1a is not AU
rich (Fig. 6). One of the main function of the exosome complex
is the degradation of ARE genes, which may explain why only
the ARE atxn1b was increased in our zebrafish models of exoso-
mal protein deficiencies.
Discussion
Here we report a homozygous missense change in the RBM7 gene
as likely cause of the disease in a patient with spinal motor
neuropathy, similar to SMA. This finding further emphasises the
important role of RNA metabolism in spinal motor neurons. The
patient developed hypotonia and failure to thrive at one month
of age, followed by delayed motor development, muscle weak-
ness and respiratory problems with normal cognition, and died of
respiratory failure at 28 months of age. Electrophysiological ex-
amination and muscle histology were all suggestive of SMA.
Exome sequencing identified a homozygous missense mutation
in RBM7, and our investigations support the pathogenic role of
this mutation in the human disease. The mutation c.236C > G;
p.Pro79Arg is located within the highly conserved RRM domain
(14) and is predicted to affect RNA binding. It resulted in severely
reduced levels of the RBM7 protein to 37% of the levels in control
cells. We also detected lower RBM7 in another patient with
EXOSC8 deficiency, suggesting a tightly regulated interaction
within the exosome and related complexes. In support of this, we
also detected lower EXOSC3 levels in EXOSC8 deficiency (19).
RBM7 is a subunit of the NEXT complex, a co-factor of the
exosome. It is an RNA binding protein known to be involved in
RNA processing in eukaryotes (14,28). Its RRM domain is com-
prised within the first 94 amino acids in humans and binds with
high specificity to U-rich or AREs (14).
It has been previously suggested, that EXOSC3, EXOSC8 and
RBM7 have different roles in the eukaryotes’ exosome. EXOSC3/
Rrp40 have RNA-binding properties, containing one Ribosomal
protein S1-like RNA-binding domain (S1) and one K homology
RNA-binding domain (KH) binding domain (10). EXOSC8/Rrp43
has a Pleckstrin homology domain, but it is not clear if it has
Figure 6. Gene expression analysis of atxn1a and atxn1b in zebrafish upon knock down of rbm7, exosc8 and exosc3. Knock down of all three genes did not affect expres-
sion of atxn1a (A) while expression of atxn1b was greatly affected by defective functionality of the exosome complex (B). Error bars indicate SD qRT-PCR analysis re-
peated three times on different biological samples. Gene expression data are in agreement with the AU-content of atxn1a and atxn1b (C). Human ATXN1 has an
AU-content similar to zebrafish atxn1b.
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phosphorolytic activities or if instead this subunit only has a
structural function (29). Finally, RBM7 has a RRM domain which
is involved in both RNA binding (14) and splicing (28).
Given the involvement of RBM7 in the cellular RNA metabo-
lism, we studied the global RNA levels in patient and control
cells by RNA-Seq analysis. We detected differential expression
of 200–300 genes in each cell lines, and 62 genes were the same
in both RBM7 and EXOSC8 mutant cells. Many of these genes
were homeobox (HOX) genes and non-coding RNAs. HOX genes
are a class of highly conserved transcription factors, and they
play a very important role during embryonal development and
mutations in these genes have very variable clinical presenta-
tions (30,37). HOX genes are divided in four clusters (A–D) in-
volved in body axis definition (31), in the development of the
limbs (32) as well as the central and peripheral nerves (33). It is
uncertain, however, whether the changes in the expression of
HOX genes relate to our patient phenotype. We also detected in-
creased levels of a special long non-coding RNA transcript,
HOTAIR in both RBM7 (5.26 log2 fold change) and EXOSC8 (7.64
log2 fold change). HOTAIR is a long non-coding RNA which was
shown to be involved in transcriptional and epigenetic regula-
tion (34), as well as in post-translational modifications (35) of
several other genes, including ataxin (ATXN1) (35). HOTAIR is lo-
cated in a transgenic region in the HOXC locus and
co-transcribes with these genes (36) and also silences the ex-
pression of the HOXD genes (36). This pattern is clearly seen in
our EXOSC8 mutant fibroblasts, where the increase in HOTAIR is
associated with reduction of HOXD10, HOXD11 and HOXD13 of
respectively 6.67, 5.37 and 4.10 Log2 fold change. These
HOXD genes have been shown to be involved in neurodevelop-
ment in humans (37) and mice (38).
To study the role of RBM7 deficiency in vivo we generated
zebrafish models of rbm7, but also of exosc8 and exosc3 deficien-
cies, the phenotype of these animals closely resembled that of
patients carrying autosomal recessive mutations in these genes.
Interestingly, we were able to observe a similar pattern of neu-
ronal defects as previously observed in a zebrafish model of
SMA both in peripheral (39) and cranial nerves (27). Knock-
down of rbm7, exosc8 and exosc3 also caused defective develop-
ment of cerebellar structures. Disruption of the structure of the
PC layer in our models is keeping with what has been previously
shown by in situ hybridisation in a zebrafish PCH1 model (17).
The cellular structure of the cerebellum and its functions are
highly conserved among all vertebrates given that it is neces-
sary to perform motor tasks, integrating sensory and motor in-
formation (40). Between 75 and 100% of exosc3-MO and exosc8-
MO fish have defective cerebellum compared with only <50% of
the rbm7-MO fish (Fig. 4I), indicating a more important role of
exosc3 and exosc8 in cerebellar development. Similarly, patients
with EXOSC8 and EXOSC3 mutations have severe pontocerebel-
lar hypoplasia (41) while the RBM7 mutation causes an SMA-like
phenotype.
Based on the observation of increased expression of HOXC
genes in human fibroblasts we tested whether this is also pre-
sent in zebrafish models of exosomal protein deficiencies.
Although we observed mild changes in the expression of some
hox genes, none of these changes were statistically significant.
No ortholog of HOTAIR has been characterised in zebrafish yet.
Based on the observation of defective cerebellar PC differentia-
tion in morphant fish, and on the fact that ATXN1 is a known
ARE gene important for PC survival we decided to investigate
further this gene after knock-down of rbm7, exosc8 and exosc3 in
zebrafish. ATXN1 is known to be linked to the pathogenesis of
spinocerebellar ataxia type 1 (42). Extended polyQ stretch within
the protein causes toxicity and neurodegeneration of PCs, the
nuclei of the brainstem cranial nerves, the inferior olives, and
the spinocerebellar tracts (43,44). ATXN1 is important for differ-
entiation of PCs in mouse (45). Neurodegeneration caused by
ATXN1 is not only due to the gain of function caused by the
polyQ extension. Also overexpression of the wild type gene
seems to be toxic in mouse as well as in Drosophila melanogaster,
indicating that higher levels of normal ATXN1 protein domains
(other than the expanded polyQ tract) might also contribute to
neurodegeneration (46,47). There are two ATXN1 paralogues in
zebrafish: atxn1a and atxn1b, both expressed in the cerebellum
as early as 28 hpf (48). Increased levels of atxn1b mRNA was
identified upon knock-down of rbm7, exosc8 and exosc3 in our
zebrafish models, which may have a toxic effect on the develop-
ment of the cerebellum leading to a defective differentiation of
PCs observed in zebrafish at 4.5 dpf. Notably, the percentage of
fish with defective cerebellar structure is directly proportional
to the level of atxn1b in the corresponding morphants. Altered
expression of other neuron-specific genes may underlie the de-
generation of motor neurons or oligodendroglia. Further studies
in neuronal cells will reveal tissue specific factors in RNA me-
tabolism, which may provide further insights to the under-
standing of neurodegenerative diseases.
Materials and Methods
Genetic analysis
Ethical approval and informed consent from the patient’s fam-
ily has been obtained for the study.
WES analysis
Exonic sequences from DNA samples of the patient were en-
riched with the SureSelect Human All Exon 50 Mb Kit (Agilent
Technologies, Santa Clara, CA, USA). Sequences (100-bp paired-
end) were generated on a HiSeq2000 (Illumina, San Diego, CA,
USA). Read alignment and variant calling were performed with
DNAnexus (Palo Alto, CA, USA) using default parameters with
the human genome assembly hg19 (GRCh37) as reference.
Sequencing of the coding region of RBM7 has been performed
by intronic primers (Supplementary Materials). Parental consent
was given for genetic studies. The study was performed with
the approval of the ethical committees of Hadassah Medical
Center and the Israeli Ministry of Health.
Cell culture
Fibroblasts of one patients carrying EXOSC8 mutations (patient
P3-II:1 in Boczonadi et al. 2014) and of the patient carrying the
RBM7 mutation and three controls were grown in high
glucose Dulbecco’s modified Eagle’s medium (DMEM, Sigma,
Poole, UK) supplemented with 10% FBS and 1% penicillin/
streptomycin.
Immunoblotting
Aliquots of total protein (20 mg) were loaded on 4–12% SDS-poly-
acrylamide gel electrophoresis, transferred to a PVDF mem-
brane with an iBlot2 PVDF Mini transfer stack and subsequently
probed with a polyclonal antibody recognizing RBM7 (Abcam
ab84116, 1:600), SNX15 (Abcam ab172534, 1:500), b-actin (Sigma
A1978, 1:2000).
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RNA-seq and bioinformatics analysis
Total RNA was isolated from primary fibroblasts using the
mirVana miRNA Isolation Kit (Ambion) and DNAse treated with
the DNA-free DNA Removal Kit (Ambion). RNA-seq libraries
were prepared using Illumina (Illumina, Inc. CA, U.S.) TruSeq
Stranded Total RNA with Ribo-Zero Human kit and were se-
quenced on an Illumina HiSeq 2500 platform using paired-end
protocol. The quality of sequencing reads was firstly checked
with FastQC (http://www.bioinformatics.babraham.ac.uk/proj
ects/fastqc/). The 12 bp on the left ends and 4 bp of the right
ends of all reads were clipped off with Seqtk (https://github.
com/lh3/seqtk) to remove GC-content biased bases. Autoadapt
was then used to remove low quality bases (Q< 20) and contam-
inations from standard Illumina paired-end sequencing adap-
tors on 30 ends of reads. Autoadapt (https://github.com/
optimuscoprime/autoadapt) uses FastQC to identify the exact
sources of contaminations and uses cutadapt (49) to remove
them automatically. Poly-N tails were trimmed off from reads
with an in house Perl script. Only reads that were at least 20 bp
in length after trimming were kept. These high quality reads
were then mapped to the human reference genome hg38 with
Tophat2 (50). Number of reads mapped to genes were counted
using HTSeq-count (51). Differentially expressed genes were
then identified with Bionconductor (52) package DESeq2 (53). P-
values of detected expression changes were corrected with
Benjamini & Hochberg algorithm. Genes differentially ex-
pressed with P-values  0.05 and fold change  2 were consid-
ered as differentially expressed genes.
Fish strains and maintenance
We used the golden zebrafish strain and the transgenic islet-
1:GFP strain (Tg(islet-1:GFP) which expresses GFP in cranial mo-
tor neurons under the control of islet-1 promoter (54). Zebrafish
embryos were collected and raised at 28.5 C in E3 medium us-
ing established procedures (55) and staged in hours or days
post-fertilization, according to the criteria established by
Kimmel et al. (56).
Antisense morpholino microinjections
We used two previously published translation blocking mor-
pholino oligonucleotides (MOs) (Genetools, LLC) for exosc3 and
exosc8 knock down (17,19). We designed two new splice blocking
morpholinos to knock down rbm7, in order to target the intron1-
exon2 boundary and the exon2-intron2 boundary. The se-
quences of the MOs were the following:
SPL rbm7_In1-Ex2-MO: 50-ATGGCCCAGCCTAGTGGAAAAAGA
A-30; SPL rbm7_Ex2-In2-MO: 50-ACGCAATAAGGAAAGTCCTA
CCGGT-30 AUG exosc8 MO: 50-TTTAAAACCAGCCGCCAT
GATGTTT-30; AUG exosc3 MO: 50- TCCATGATGGAGGAGCGGA
AAACAC-30; CTRL MO: 50-CCTCTTACCTCAGTTACAATTTATA-30.
Morpholinos were re-suspended in 1Danieau solution
[0.4 mM MgSO4, 58 mM NaCl, 0.7 mM KCl, 5 mM HEPES, 0.6 mM
Ca(NO3)2; pH 7.6] with Phenol Red (56). Embryos were injected
up to two cells stage of development with 1.5 ng of exosc3 MO,
10 ng of exosc8 MO and 2.2 ng of rbm7 MO. The Gene Tools stan-
dard control MO was used for control injections. The dose of MO
was optimized by injecting several doses until a range of differ-
ent phenotypes was obtained. At least three independent mi-
croinjections were performed to study the phenotype caused by
each MO. The transgenic islet-1:GFP fish strain was used to
study cranial motor neuron abnormalities and the ‘golden’
strain was used for immunostaining and qRT-PCR. Zebrafish of
the islet-1:GFP strain were anesthetized with Tricaine solution
and phenotyped at 48 hpf to assess brain morphology. Images
were captured using a MZ16F fluorescent stereomicroscope
(Leica).
Whole mount antibody immunofluorescence
For whole-mount immunofluorescence staining, ‘golden’ zebra-
fish embryos and larvae were fixed in 4% paraformaldehyde in
phosphate-buffered saline overnight at 4C and then permeabi-
lized in cold acetone at 20C. In addition, 4-dpf-old larvae were
permeabilized with collagenase A (Roche Diagnostics, 1 mg/ml)
for 90 min. Embryos/larvae were blocked in 5% horse serum in
phosphate-buffered saline containing 0.1% Tween-20 (PBT).
Embryos/larvae were incubated in blocking solution containing
primary antibody overnight at 4C followed by washing several
times with PBT and incubation with secondary antibody (1:500
anti-mouse Alexa Fluor 488, Invitrogen). Primary antibodies
used in this study were: Parvalbumin7 (1:1000, mouse ascites)
was used for PCs staining (kind gift of Prof. Masahiko Hibi,
Nagoya University, Japan) as previously described in (57); SV2
(1:200, Developmental Studies Hybridoma Bank, Iowa) was used
for staining synaptic vesicles. Acetylcholine receptors were vi-
sualized by using Alexa Fluor 594 conjugated a-bungarotoxin
(1lg/ml, Invitrogen). Embryos were imaged in methyl cellulose
using a Nikon A1R confocal. Z-stack images were generated by
scanning through the whole body with a 10 objective and then
images manipulated to have the best resolution with NIS-
element AR 3.2 64 bit software.
Image analysis
For measuring motor neuron axon length, a total number of five
fish with a mild phenotype were randomly chosen from each
morphant group and shorter axons were measured. Measuring
was performed with NIS-element AR 3.2 64 bit software. In order
to have an indicative estimation of the defect, an axon length/
somite length ratio was calculated.
RNA isolation, RT-PCR and gene expression analysis
in zebrafish
RNA from zebrafish embryos was isolated using Trizol reagent
(Invitrogen, Paisley, UK) following manufacturer’s instructions.
For RT-PCR analysis following MO microinjection, RNA from
about 30 embryos was isolated and 1 lg of RNA for reaction was
reverse transcribed with High capacity cDNA reverse transcrip-
tion kit (Applied Biosystems).
Primers used were: Fw 50-TTGACGCGATTAACCGACTG-30;
Rv50- GGAGAGTAAGACGGAGAGCC-30. Individual bands were
purified and sequenced.
RNA from fibroblasts and fish for qRT-PCR was extracted us-
ing the RNAeasy mini kit (Qiagen) following manufacturer in-
structions and then treated with DNA-free Kit (Ambion) in order
to remove genomic DNA contamination. 2 lg of RNA was used
to synthesize cDNA with the high capacity cDNA reverse tran-
scription kit (Applied Biosystems). The cDNA was diluted in or-
der to have the equivalent of 25 ng of RNA/reaction. qRT-PCR
(Biorad Iight-cycler equipped with a MyIQ detection system)
was performed in triplicates. qRT-PCR primers are listed in
Supplementary Material, Table S4.
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